Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma...

詳細記述

保存先:
書誌詳細
主要な著者: Frank-Kamenetsky, Maria, Grefhorst, Aldo, Anderson, Norma N., Racie, Timothy S., Bramlage, Birgit, Akinc, Akin, Butler, David, Charisse, Klaus, Dorkin, Robert, Fan, Yupeng, Gamba-Vitalo, Christina, Hadwiger, Philipp, Jayaraman, Muthusamy, John, Matthias, Jayaprakash, K. Narayanannair, Maier, Martin, Nechev, Lubomir, Rajeev, Kallanthottathil G., Read, Timothy, Röhl, Ingo, Soutschek, Jürgen, Tan, Pamela, Wong, Jamie, Wang, Gang, Zimmermann, Tracy, de Fougerolles, Antonin, Vornlocher, Hans-Peter, Langer, Robert, Anderson, Daniel G., Manoharan, Muthiah, Koteliansky, Victor, Horton, Jay D., Fitzgerald, Kevin
フォーマット: Artigo
言語:Inglês
出版事項: National Academy of Sciences 2008
主題:
Biological Sciences
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2575310/
https://ncbi.nlm.nih.gov/pubmed/18695239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0805434105
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料